Navigation Links
Silence Therapeutics Announces Board Changes
Date:7/1/2008

Appoints Annette Clancy and Jerry Randall as non-executive directors

LONDON, July 1 /PRNewswire/ -- Silence Therapeutics plc (London AIM: SLN) ('the Company') today announced changes to its Board of Directors as part of the company's plan for growth.

Effective today, Silence has appointed Annette Clancy and Jerry Randall as non-executive directors and Iain Rugheimer has resigned as a director of the Company.

Annette Clancy is joining the Board in her first non-executive director role. Ms. Clancy (53) is currently with GlaxoSmithKline (GSK), where she has had a distinguished career spanning 30 years, and will be leaving GSK at the end of the year. She has 15 years experience in Business Development, leading GSK's global Transactions and Alliance Management teams for the past 3 years, and during her tenure she and her team have been responsible for concluding a large number of research, development and commercial business collaborations on behalf of GSK. Prior to her role in Business Development, Ms. Clancy held a number of positions in Clinical Research, R&D project management and Commercialization. Ms. Clancy has a BSc (Hons) Pharmacology from Bath University.

Jerry Randall has been Chief Financial Officer of Sinclair Pharmaceuticals plc since 2000 when he joined as part of a management buy-in team. Prior to this, Mr. Randall worked in corporate finance with Gambit Corporate Finance. Previously, Mr. Randall had been involved in two other buy-ins and acted as adviser to both private and quoted companies between 1993 and 2000, in both the capacity as nominated adviser and in practice with KPMG. During this period, Mr. Randall (43) was involved in a number of flotations and transactions on the Official List, Unlisted Securities Market and the Alternative Investment Market, as well as raising private equity. Mr. Randall qualified as a chartered accountant with KPMG in 1990. Mr. Randall has a beneficial interest in 10,000 ordinary share
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
2. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
3. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...clinical program to evaluate TAXUS(R) Element(TM) ...Stent, NATICK, Mass., Oct. 8 /PRNewswire-FirstCal...today announced that it has completed enrollment i...any,s third-generation,TAXUS(R) Element(TM) paclit...program has enrolled nearly 1,500 patients at 100 ...
(Date:10/7/2008)...DIEGO, Oct. 7 /- Prometheus Laborator...y announced findings from its,development of PROME...test,for irritable bowel syndrome (IBS). The findi...on of particular biomarkers in blood samples,betwe... these biomarkers,combined with a proprietary alg...
(Date:10/7/2008)...lts of FLEXX Trial Presented at the Osteoarthritis...ess, PARSIPPANY, N.J., Oct. 7 /- Fer...ts from the FLEXX Trial of Osteoarthritis of the,K...te), a highly pure,non-avian high molecular weight...is superior to intra-articular saline (IA-saline) ...
(Date:10/7/2008)... clinical study of adults, VYVANSE taken once-dail...in one week, PHILADELPHIA, Oct. 7 /PRNewswire-Fir...e global specialty biopharmaceutical company, toda...r issue of the Journal of,Clinical Psychiatry foun...ion Deficit Hyperactivity Disorder (ADHD) symptoms...
Breaking Medicine Technology:Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Tongji Hires German Based Dr Petri Consulting GmbH for Langdong Project 24446 1Tongji Hires German Based Dr Petri Consulting GmbH for Langdong Project 24446 2Psychemedics Corporation Announces Second Quarter Results 24442 1Psychemedics Corporation Announces Second Quarter Results 24442 2Psychemedics Corporation Announces Second Quarter Results 24442 3Psychemedics Corporation Announces Second Quarter Results 24442 4Psychemedics Corporation Announces Second Quarter Results 24442 5Arcadia Radiology Medical Group Chooses AMICAS 6758 1Arcadia Radiology Medical Group Chooses AMICAS 6758 2Arcadia Radiology Medical Group Chooses AMICAS 6758 3Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 1Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 2Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 3Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 4
...pyridopyrazine-urea derivative compound series sho...e valuable for cancer,treatment , , QUBEC C... (TSX: AEZ; Nasdaq:,AEZS), a global, pure play b...erapy and oncology, today presented an abstract,...e derivatives,with high selectivity for PI3K inh...
...SINESS WIRE)--Apr 17, 2007 - Alnylam,Pharmaceutica...cs,company, announced today at the American Associ...ng that it will advance a,systemically delivered R...iver cancer and potentially other solid tumors as ...erapeutic that is,designed to target vascular endo...
Other Medicine Technology:terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 2Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 3Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 5
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
... nonsurgical image-guided treatment of kidney tumo...copic// technique in viable candidates. The resear...Radiology’s 32nd Annual Scientific Meeting. The ...ous cryoablation results in a slightly lower recur...
...s to help stroke survivors with the kind of comple...outside the box," according// to a University of I...participants' abilities were independent of any ch...improvements in complex mental abilities were not ...
...n are at a higher risk of perinatal mortality (dea...ies born to black or white women// , concludes a s... Health Organisation defines post-term pregnancy a...irst day of the last menstrual period. Post-term p...
...orld's largest maker of generic drugs and 19 other...ine medicines without federal approval. The Food ...s were part of an effort to halt the marketing of ...drugs. The goal is to get the unapproved drugs off...
Other Medicine News:Health News:Freezing Kidney Tumors Effective and Less Expensive Than Laparoscopy 2Health News:Antidepressants Improve Post-Stroke Mental Abilities 2Health News:Antidepressants Improve Post-Stroke Mental Abilities 3Health News:FDA Warns Migraine Medicine Makers 2
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer
...al growth system, combines orbital shaking, oxygen...r bacterial growth. It is designed for easy integr...Extractor. The uniquely engineered HT-MegaGrowTM h...akers. Plate-holding cassettes allow for high plat...
Inquire
Inquire
Medicine Products: